A Study of Zanidatamab in People With Solid Tumor Cancer

Full Title

A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants with Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Vicky Makker’s office at 646-888-4224.